MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. (March 2023)

• Record Type: Journal Article
• Authors: Chatterjee, Fiona; Spranger, Stefani
• Is Part Of: Seminars in immunology. Volume 66(2023)
• Publication Date: 2023-03
• Subjects: DC dendritic cell -- APC antigen presenting cell -- cDC conventional dendritic cell -- pDC plasmacytoid dendritic cell -- cDC1 type 1 conventional dendritic cell -- cDC2 type 2 conventional dendritic cell -- MHC-I major histocompatibility complex class I -- BMDC bone marrow-derived dendritic cell -- OT-I T cells SIINFEKL-H-2Kb-specific TCR-transgenic T cells -- ECV extracellular vesicle -- SIINFEKL ovalbumin CD8+ antigen -- VSV vesicular stomatitis virus -- LCMV lymphocytic choriomeningitis virus -- SCT single chain trimer -- ER endoplasmic reticulum -- mTEC medullary thymic epithelial cell; Dendritic cell -- MHC-dressing -- Cross-presentation -- CD8+ T cell; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Immunity -- Periodicals; Immunologie -- Périodiques; Electronic journals; 616.079
• DOI: 10.1016/j.smim.2023.101710
• Languages: English
• ISSNs: 1044-5323

Abstract

Abstract: Dendritic cells are crucial for anti-tumor immune responses due to their ability to activate cytotoxic effector CD8 + T cells. Canonically, in anti-tumor immunity, dendritic cells activate CD8 + T cells in a process termed cross-presentation. Recent studies have demonstrated that another type of antigen presentation, MHC-dressing, also serves to activate CD8 + T cells against tumor cell-derived antigens. Understanding MHC-dressing's specific contributions to anti-tumor immunity can open up novel therapeutic avenues. In this review, we summarize the early studies that identified MHC-dressing as a relevant antigen presentation pathway before diving into a deeper discussion of the biology of MHC-dressing, focusing in particular on which dendritic cell subsets are most capable of performing MHC-dressing and how MHC-dressing compares to other forms of antigen presentation. We conclude by discussing the implications MHC-dressing has for anti-tumor immunity. Highlights: Tumor-specific CD8 + T cells can be primed via MHC-dressing. Both subsets of conventional dendritic cells can utilize MHC-dressing to prime CD8 + T cells. The dendritic cell activation state, determined by tumor-derived factors, affects the ability of dendritic cells to prime CD8 + T cells via MHC-dressing.